Floatz logo

Tilsotolimod

Refractory Solid Tumors

Idera Pharmaceuticals, Inc.nucleic_acidPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Refractory Solid Tumors cohort.

Asset / SponsorPhaseRating
Rapamycin
Samsung Medical Center
Phase 4BB
su011248
Samsung Medical Center
Phase 4BB
Valproic Acid
National Institute of Cancerología
Phase 2B
Hydralazine
National Institute of Cancerología
Phase 2B
(+)-VINCRISTINE
Theodore Laetsch
Phase 1/2CCC

View all 36 →

Same molecule, other indications

Tilsotolimod is also rated in:

metastatic melanomaDormant
B
Indicative ·
59 / 100
View asset →
melanomaDormant
B
Indicative ·
58 / 100
View asset →
Advanced Solid Tumors CancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →